Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01807598 (Clinical Trial / Brentuximab vedotin / SGN-035 / Adcetris®)

Study Title
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia (NCT01807598)

Trial Description
This pilot clinical trial studies brentuximab vedotin (also known as SGN-035; Adcetris® by Seattle Genetics Inc.) in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

This trial is sponsored by Jason Robert Gotlib, Stanford University/National Cancer Institute (NCI). [1]

Study Data

  • Condition: Mastocytosis or Mast Cell Leukemia
  • Interventions:
    • Drugs used in this trial
    • Other:
      • laboratory biomarker analysis
      • questionnaire administration
    • Procedure:
      • quality-of-life assessment
  • Phase:
  • Estimated Enrollment: 11
  • Start: September 2013
  • Estimated Completion: January 2016
  • Last verified: January 2015

Study Schematic 

NCT01807598 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar